<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34469713</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-678X</ISSN><JournalIssue CitedMedium="Internet"><Volume>363</Volume><PubDate><Year>2021</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of neuroscience methods</Title><ISOAbbreviation>J Neurosci Methods</ISOAbbreviation></Journal><ArticleTitle>Aptamer-based enrichment of TDP-43 from human cells and tissues with quantification by HPLC-MS/MS.</ArticleTitle><Pagination><StartPage>109344</StartPage><MedlinePgn>109344</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jneumeth.2021.109344</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0270(21)00279-X</ELocationID><Abstract><AbstractText Label="BACKGROUND">There is great interest in detecting, characterizing and quantifying transactive response DNA binding protein of 43&#xa0;kDa (TDP-43), and its post-translational modifications, due to its association with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis. Unfortunately, detailed analysis of TDP-43 in human biological matrices by immunometric methods has been hindered by the relatively low abundance of TDP-43 and poor antibody reagent specificity.</AbstractText><AbstractText Label="NEW METHOD">With the goal of developing a selective and multiplex method for characterizing TDP-43, we previously developed a high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) assay for relative quantification of TDP-43 in human brain tissue and cells. To improve analytical sensitivity and to perform absolute quantification, we coupled a novel RNA-based aptamer enrichment workflow (and inclusion of a stable isotope-labeled standard) to HPLC-MS/MS.</AbstractText><AbstractText Label="RESULTS">The TDP-43 aptamer-enrichment-HPLC-MS/MS assay was linear from 0.37 to 2.55nmol/L, a range suitable for analysis of both human cells and brain tissue homogenates, and had a total CV of 14.8%. Quantitative TDP-43 peptide profiles were developed for cases of FTD with TDP-43 pathology and cases with no neurodegenerative pathology.</AbstractText><AbstractText Label="COMPARISON WITH EXISTING METHODS">Compared to immunoenrichment, aptamer-enrichment yielded cleaner recoveries of TDP-43. The aptamer-enrichment-HPLC-MS/MS method, compared to our previous method without enrichment, increased analytical sensitivity by 8.7-fold and 11.8-fold for endogenous TDP-43 in human cells and brain tissue, respectively. Critically, inclusion of the aptamer enrichment step improved sequence resolution and enabled identification of TDP-43 C-terminal fragments.</AbstractText><AbstractText Label="CONCLUSIONS">The aptamer-enrichment-HPLC-MS/MS method enabled highly selective quantification, enhanced sequence coverage and structural characterization of endogenous TDP-43.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pobran</LastName><ForeName>Taylor D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mackenzie</LastName><ForeName>Ian R A</ForeName><Initials>IRA</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada; Department of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeMarco</LastName><ForeName>Mari L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada; Department of Pathology and Laboratory Medicine, St. Paul's Hospital, Providence Health Care, Vancouver, Canada. Electronic address: mdmrco@mail.ubc.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neurosci Methods</MedlineTA><NlmUniqueID>7905558</NlmUniqueID><ISSNLinking>0165-0270</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="Y">Tandem Mass Spectrometry</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aptamer</Keyword><Keyword MajorTopicYN="N">Frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">Mass spectrometry</Keyword><Keyword MajorTopicYN="N">Protein misfolding</Keyword><Keyword MajorTopicYN="N">Transactive response DNA-binding protein 43&#xa0;kDa</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>1</Day><Hour>20</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34469713</ArticleId><ArticleId IdType="doi">10.1016/j.jneumeth.2021.109344</ArticleId><ArticleId IdType="pii">S0165-0270(21)00279-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>